Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesaglitazar versus glibenclamide monotherapy in type 2 diabetes
2004-000347-14Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tesaglitazar in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AstraZeneca. Primary endpoint: Absolute change in glycosylated haemoglobin A1c (HbA1c) from baseline to end of randomized treatment period. Started Jul 2004; status: completed.
02
Drugs
tesaglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2004-000347-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000347-14.